SGHT
Sight Sciences, Inc.About SGHT
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Company
- Headquarters
- Menlo Park, CA
- Employees
- 186 (2026)
- Listed
- Jul 15, 2021
- Exchange
- Nasdaq
- Website
- sightsciences.com
- SEC industry
- Surgical & Medical Instruments & Apparatus
- Cylvex sector
- Health Care · Medical Devices
Medical Devices
- Market cap #65 of 163
- P/B #28 of 152
Ranked highest first among stocks Cylvex covers.
- ABTAbbott Laboratories$199.9B+5.62%
- ISRGIntuitive Surgical Inc$170.4B+9.41%
- MDTMedtronic plc$134.3B+6.19%
- SYKStryker Corporation$130.4B+9.44%
- BSXBoston Scientific Corp.$66.40B+5.32%
Financial summary
Related companies
About
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.